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The insulin like growth factors (IGF-I and -II) are struc-
turally and functionally related to insulin. While insulin is
a key regulator of glucose homeostasis over the short term,
emerging evidence suggests that the IGFs are involved in
the longer term glucose homeostasis, possibly by modulat-
inginsulinsensitivity.Unlikeinsulin,theIGFsarepresentin
most biological ﬂuids as complexes with high afﬁnity bind-
ingproteins,theinsulin-likegrowthfactorbindingproteins
(IGFBPs). The IGFBPs regulate the bioavailability of the
IGFs. Of the six IGFBPs identiﬁed there is evidence from
studies in transgenic mice that both IGFBP-1 and IGFBP-3
may have a role in glucose regulation.
Keywords Forkhead Transcription Factors; Insulin Resistance;
Insulin Response Elements; Transgenic Mice
INTRODUCTION
The insulin-like growth factors, IGF-I and -II, share struc-
tural and functional similarities with insulin. Together with in-
sulin, they make up a family of phylogenetically conserved
molecules important in the regulation of both growth and
metabolism. Inadequate nutrition is an important constraint
on growth. Mechanisms have evolved to regulate partitioning
of caloric intake between growth and basal metabolism nec-
essary for survival of the individual and propagation of the
species.
It is not surprising that molecules that are important in the
regulation of growth are also important in the regulation of
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metabolism. No better example of this concept exists than the
IGF system where not only the ligands, IGF-I and IGF-II, but
also the receptor and the postreceptor signal transduction path-
wayssharestrikingsimilaritieswithinsulin,themajorhormone
involved in glucose and lipid metabolism, the insulin receptor,
and the insulin receptor signal transduction pathways. In lower
species, common ancestral molecules exist and probably func-
tion both as metabolic regulators such as insulin and growth
factors such as the IGFs. In higher organisms, although there is
some redundancy, the metabolic and growth-promoting func-
tions have been assigned to separate molecules. Insulin, or in-
sulins(insomehigherspeciesmorethanoneinsulingeneisex-
pressed), functions predominantly as regulator of metabolism,
whereas IGF-I and IGF-II function predominantly as growth
regulators. In addition, growth hormone, the major modula-
tor of IGF-I and other components of the IGF system, such
as insulin-like growth factor–binding protein (IGFBP)-3 and
acid-labile subunit, has insulin-like effects in adipocytes in
vitro(ErikssonandToenqvist,1997;RidderstaleandTornqvist,
1996) and modulates insulin sensitivity by a variety of mecha-
nisms (Rizza et al., 1982; Takano et al., 2001).
A major difference between insulin and the IGFs is the pres-
ence of the IGFBPs that have high afﬁnity for the IGFs. In this
chapter,IwillreviewtheemergingevidencethattheIGFsystem
has a role in glucose homeostasis. In particular, I will focus on
the role of the IGFBPs in modifying the hypoglycemic effects
of the IGF-I and -II and the recent data from transgenic mouse
models.
THE HYPOGLYCEMIC EFFECTS OF THE IGFs
Although the IGFs have insulin-like effects on glucose
homeostasis and can indeed substitute for insulin in in-
sulinopenicanimalmodelsofdiabetes(Barrettetal.,1989)and
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in diabetic patients (Laager et al., 1993; Morrow et al., 1994;
Schoenle et al., 1991), they are considerably less potent than
insulin in lowering blood sugars, reﬂecting their much lower
afﬁnity for the insulin receptor (Hintz et al., 1972; Marshall
et al., 1974; Zapf et al., 1978). However, in most mammals, the
IGFs are present in the plasma in concentrations almost 100-
fold in excess of insulin. The presence of IGFBPs effectively
reduces the free IGF plasma concentrations to levels compara-
bletoinsulin.AmajorprobleminourunderstandingoftheIGF
system in various physiological states is the lack of a reliable
assay technique that measures free IGF-I and IGF-II. Various
techniquescurrentlyavailable,suchasequilibriumdialysisand
antibodycapture,resultinperturbationssuchthatthemeasured
free IGF-I and -II probably more accurately reﬂects “easily
dissociable IGF.” The latter may include a portion of the IGF
bound to the binding proteins. Because the binding proteins
differ in their afﬁnities for IGF-I and -II, the “easily dis-
sociable IGF fraction” measured in such assays may reﬂect
some component of IGF-I or -II bound to certain binding
proteins.
Administration of IGF-I in doses necessary to lower blood
sugar in diabetic subjects and animals to levels comparable to
those seen with insulin has slightly different effects in terms
of tissue glucose uptake and inhibition of gluconeogenesis and
proteincatabolism(Laageretal.,1993).Forexample,inhuman
subjects given IGF-I or insulin to achieve comparable glucose
disappearance rates, IGF-I preferentially enhanced peripheral
glucose uptake and augmented the decrease in whole body pro-
teinbreakdowncomparedtoinsulinbuthadalessmarkedeffect
on suppression of hepatic glucose output (Laager et al., 1993;
Barrett et al., 1989; Tomas et al., 1996). This may reﬂect the
known differences in tissue distribution of insulin and IGF-I
receptors, but there may also be tissue differences in postrecep-
tor signaling pathways, local IGFBP abundance, and proteases
involved in degradation of insulin or the IGFs.
Skeletal muscle has abundant IGF-I receptors, whereas adi-
pose and hepatic tissues have fewer IGF-I receptors and are
therefore less responsive to IGF-I than muscle (Jacob et al.,
1989; Tomas et al., 1993). To add further confusion, there
is also a variable abundance of hybrid insulin/IGF-I recep-
tors. These hybrid receptors are more abundant in skeletal
muscle and are functionally more similar to insulin receptors
(Siddle et al., 1994; Pandini et al., 2002; Federici et al., 1998a,
1998b, 1999). Despite being functionally similar to insulin re-
ceptors and coupled to signal transduction pathways involved
in metabolic processes rather than mitogenic processes, these
receptors preferentially bind IGF-I compared to insulin. Fur-
thermore, the relative abundance of hybrid receptors varies in
different physiological states. Hyperinsulinemia seen in pa-
tients with type 2 diabetes and patients with insulinomas is
associated with a down-regulation of insulin receptors and an
increase in hybrid receptor abundance (Federici et al., 1998a,
1998b).
IGF-I has proven to be therapeutically useful in treating di-
abetic patients with severe insulin resistance (Cheetham et al.,
1994; Morrow et al., 1994; Schoenle et al., 1991). This ef-
fect may be due to its action on the IGF-I receptor, a pref-
erential effect of IGF-I on IGF-I/insulin hybrid receptors, or
possibly via sensitization of post–insulin receptor signal trans-
duction pathways. A similar insulin-sensitizing effect of IGF-I
in streptozotocin-treated rats has been observed, although the
mechanismsresponsiblehavenotbeenelucidated(Tomasetal.,
1993).
THE ROLE OF THE IGFBPs
IN GLUCOSE HOMEOSTASIS
Six IGFBPs have been identiﬁed and characterized and iso-
forms of a number of these are present in various biological
ﬂuids. These isoforms result from post-translation modiﬁca-
tion such as N-glycosylation for IGFBP-3 and -4 (Wood et al.,
1988; Ceda et al., 1991), O-glycosylation for IGFBP-6 (Bach
etal.,1992),andphosphorylationforIGFBP-1,-3,and-5(Elgin
et al., 1987; Frost and Tseng, 1991; Hoeck and Mukku, 1994;
Coverley and Baxter, 1997). Overall amino acid sequence sim-
ilarity between the IGFBPs varies from 47% to 60%, with
IGFBP-3 and -5 being the most closely related. Similarity is
greatestattheaminoandcarboxylendsofthebindingproteins,
the regions of these proteins that are involved in formation of
the high-afﬁnity IGF binding site. The mid region of the IGF-
BPs shows the most sequence variation (Shimasaki and Ling,
1991; Rechler, 1993). The molecular pocket for high-afﬁnity
binding of IGF-I is generated by both the amino- and carboxyl-
terminal ends, which are kept in close proximity to one another
bythesecondarystructureoftheIGFBPs,dictatedbythehighly
conserved cysteine residues.
The functional role of the binding proteins in glucose home-
ostasisisunclear.Asimplisticviewisthattheyservetoblockthe
insulin-like activity of the relatively large concentrations of the
IGFspresentinthecirculationyetfacilitatedeliveryoftheIGFs
to tissues to exert the anabolic effects of IGFs (Baxter, 1994).
Indeed,thediscoveryoftheIGFBPsdatesbacktotheuseofthe
ratfatpadbioassaytomeasurenonsuppressibleinsulin-likeac-
tivity in plasma (Burgi et al., 1966). The fortuitous observation
that activity of plasma samples in this assay could be enhanced
by acid-ethanol extraction was the ﬁrst clue to the existence of
the binding proteins. A number of investigators have been able
to demonstrate that the IGFBPs are able to inhibit the biologi-
cal actions of the IGFs in various bioassays, including those in
whichglucoseuptakewasmeasured(Meulietal.,1978;KnauerIGFS, IGFBPS, AND GLUCOSE HOMEOSTASIS 215
and Smith, 1980; Burch et al., 1990; Ritvos et al., 1988). For
example, IGFBP-3 is able to inhibit the IGF-I effect on lipoge-
nesis and glucose oxidation in porcine adipose tissue (Walton
et al., 1989).
Severalstudiessuggestthattheeffectsofthebindingproteins
on IGF-I action may not be simple inhibition. Combinations of
IGF and IGFBP-3 are more potent in a variety of in vitro and
in vivo assay systems than IGF-I alone (DeMellow and Baxter,
1988;Bagietal.,1994,1995;Clemmonsetal.,2000).Thebind-
ing proteins themselves appear to be able to interact with cell
surfaceproteinsandmayfacilitatedeliveryoftheIGFstotarget
cells (DeVroede et al., 1986), and this may explain the in vitro
enhancement of IGF-I action, whereas prolongation of biologi-
calhalf-lifeofIGF-IanddifferentialtissueuptakeofIGF-Imay
account for the enhanced biological potency of the IGFBP-3/
IGF-Icomplexinvivo(Bagietal.,1994,1995).Similarly,non-
phosphorylated IGFBP-1 can enhance the activity of IGF-I un-
der certain circumstances, at least in vitro (Elgin et al., 1987).
The majority of the insulin-like activity present in serum is
due to the IGFs rather than insulin itself (Burgi et al., 1966).
Because most of the IGF-I and -II present in the circulation is
boundtotheIGFBPs,predominantlyIGFBP-3,insulinisableto
acutely regulate the blood glucose. Notwithstanding this, free,
unbound IGF-I and -II, which constitute a small proportion of
the total IGFs present in plasma (Frystyk et al., 1999), may
have some role in short-term glucose regulation. Several types
ofdatasupportthishypothesis.Theseincludetheacutechanges
in IGFBP-1 expression that accompany food intake (Murphy
et al., 1991), the hyperglycemia that accompanies infusion of
IGFBP-1 (Lewitt et al., 1991) and IGFBP-3 (Vuguin et al.,
2001), the glucose intolerance observed in liver-speciﬁc IGF-
I knockout mice (Yakar et al., 2001), and the hyperglycemia
observedinTgmiceoverexpressingIGFBP-1(Rajkumaretal.,
1995) and IGFBP-3 (Silha et al., 2002).
OfthesixIGFBPs,thereisconvincingevidencethatIGFBP-
1 and -3 are involved in glucose homeostasis. As yet there are
no reports that directly address the role of the other binding
proteins in glucose homeostasis.
IGFBP-1 and Glucose Homeostasis
Although this binding protein probably constitutes a rela-
tively small proportion of the total IGF-binding capacity of
serum from adult rodents and human subjects, its abundance
in the plasma and its expression in various tissues is acutely
regulated in response to nutritional deprivation and is tightly
regulated by insulin (Suikkari et al., 1988, 1989). These ob-
servations following the developments of a reliable radioim-
munoassayandmolecularprobesforIGFBP-1providedtheini-
tial clue that IGFBP-1 may have a role in regulating metabolic
homeostasis.
IGFBP-1hasashorthalf-lifeinthecirculation(Lewittetal.,
1991), possibly due to the fact that, unlike some other IGFBPs,
it is not glycosylated. In addition, IGFBP-1 has a Pro-Glu-Ser-
Thr sequence that is present in many proteins that have a rapid
turnover(Julkunenetal.,1988).IGFBP-1appearstobepresent
in plasma and other biological ﬂuids in multiple isoforms and
a least one form of human IGFBP-1 can actually enhance the
action of IGF-I (Elgin et al., 1987). The isoforms of IGFBP-1
appear to be the result of phosphorylation (Frost and Tseng,
1991) although other post-translational modiﬁcations have not
beenextensivelyinvestigated.IGFBP-1undergoesserinephos-
phorylation that enhances its afﬁnity for IGF-I by six- to eight-
fold. Phosphorylation of IGFBP-1 also enhances its ability to
inhibit IGF-I actions, including the hypoglycemic effects of
IGF-I (Sakai et al., 2001).
In both human subjects and rodents, plasma IGFBP-1 con-
centrations appear to be inversely correlated with serum in-
sulin levels (Murphy et al., 1991; Suikkari et al., 1988) and
elevated IGFBP-1 concentrations are apparent in normal indi-
vidualsafteranovernightfast(BaxterandCowell,1987;Busby
et al., 1988). Insulin markedly suppresses IGFBP-1 synthesis
in liver explants (Lewitt and Baxter, 1989) and this can be ex-
plained by a suppressive effect of insulin on IGFBP-1 gene
transcription. This inhibition of IGFBP-1 expression is medi-
ated via an insulin response element (IRE) (Unterman et al.,
1992; Suwanichkul et al., 1993; Robertson et al., 1994). The
IRE motif, CAAAA(C/T)AA, is similar to that found in other
insulin-inhibited genes and interacts with forkhead type tran-
scriptionfactor,FKHR(Renaetal.,1999),thehomologueofthe
forkhead/winged-helix transcription factor daf-16 identiﬁed in
Caenorhabditas elegans (Ogg et al., 1997). Insulin, and proba-
bly IGF-I also, working via activation of the phosphatidylinos-
itol 3-kinase pathway, leads to protein kinase B/Akt-mediated
phosphorylation of FKHR. In its nonphosphorylated form,
FKHR interacts with the IRE and trans-activates IGFBP-1 ex-
pression (Durhan et al., 1999). As a consequence of this serine
phosphorylation,thereisnuclearexportofFKHRanddisrupted
trans-activation of IGFBP-1 and other insulin-regulated genes
(Guo et al., 1999). Cotransfection of antisense FKHR also in-
hibits IGFBP-1 transcription, indicating that the interaction of
the nonphosphorylated FKHR with the IRE is responsible for
basal IGFBP-1 transcription. In hepatocytes with abundant in-
sulin receptors and sparse IGF-I receptors, insulin is proba-
bly the major regulator of FKHR phosphorylation, whereas in
othercelltypeswhereIGF-Ireceptorsareabundant,IGF-Imay
be more important in regulating FKHR phosphorylation (Rena
etal.,1999).ThisisofpotentialrelevancebecauseFKHRphos-
phorylationisimportantnotonlyintheexpressionofIGFBP-1,
whoseexpressionislargelyrestrictedtotheliver,butalsoinreg-
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homeostasis. Furthermore in the nematode, daf-16 is critically
important in regulating the changes in metabolism that accom-
pany the quiescent phase of the nematode life cycle (Ogg et al.,
1997).
In addition to reduced circulating IGF-I concentrations, it
has been long appreciated that plasma from diabetic animals
also contains factors that are able to inhibit IGF action in carti-
lage bioassays (Phillips et al., 1979). Although the nature and
functional role of these inhibitors have never been fully clar-
iﬁed, it appears that part, or possibly most, of this inhibitory
activity is due to enhanced IGFBP concentrations, in particu-
lar IGFBP-1. An increased concentration of IGFBP-1 in sera
from diabetic rats was initially reported by Unterman’s group
(Untermanetal.,1992)andsubsequentstudiesdemonstratedan
increaseinIGFBP-1mRNAexpressioninhepaticandrenaltis-
suesfromstreptozotocindiabeticrats(LuoandMurphy,1991).
Administration of insulin to diabetic rats resulted in a de-
crease in IGFBP-1 gene transcription, and IGFBP-1 in the
circulation.
The regulation of IGFBP-1 in relationship to nutrition sug-
gestedthatthisbindingproteinisinvolvedinregulatingglucose
homeostasis. Initially, studies with infused human plasma-
derived IGFBP-1 in rats demonstrated only a modest hyper-
glycemic effect. However, this initial observation was convinc-
ingly conﬁrmed using transgenic mouse technology. Several
groups have now generated transgenic mice overexpressing
IGFBP-1 (Dai et al., 1994; Rajkumar et al., 1995; Gay et al.,
1997; Crossey et al., 2000). In most (Rajkumar et al., 1995;
Crossey et al., 2000) but not all (Dai et al., 1994) reports,
mild glucose intolerance and/or hyperglycemia were reported
in the IGFBP-1 transgenic mice. In addition, Rajkumar and
colleagues (1996b) demonstrated that the hypoglycemic effect
of IGF-I, but not that of des (1–3) IGF-I, an analog with lit-
tle afﬁnity for IGFBP-1, was markedly attenuated in IGFBP-1
transgenic mice (Figures 1 and 2).
In addition to the levels and tissue distribution of expression
of the transgene, the phosphorylation status of the IGFBP-1
transgene appears to be important in the modulation of glu-
cose homeostasis. This was clearly illustrated by comparison
oftransgenicmicethatexpresshumanIGFBP-1orratIGFBP-1
transgenes (Sakai et al., 2001). Both strains of mice expressed
high concentrations of IGFBP-1 in serum and tissues. How-
ever, human IGFBP-1 transgenic mice did not show glucose
intolerance and exhibited no signiﬁcant intrauterine growth re-
tardation (Dai et al., 1994), whereas rat IGFBP-1 transgenic
mice showed fasting hyperglycemia and intrauterine growth
restriction (Rajkumar et al., 1996a). The explanation for this
difference appears to be related in part to the phosphorylation
state of the transgene product. Only half of the IGFBP-1 in
serum from the human IGFBP-1 transgenic mice was phos-
FIGURE 1
Glucose intolerance in IGFBP-1 transgenic mice. The plasma
glucose response to an intraperitoneal glucose challenge.
(Reproduced with permission from Rajkumar et al., 1996b.)
phorylated, whereas most of the IGFBP-1 in the serum of the
mice expressing the rat IGFBP-1 was phosphorylated (Sakai
et al., 2001). This difference may be due to relative inability of
the mouse IGFBP-1 kinase to phosphorylate human IGFBP-1
compared to rat IGFBP-1. Kinase activity puriﬁed from mouse
liver cells phosphorylate mouse and rat IGFBP-1 in vitro, but
it did not phosphorylated human IGFBP-1 (Sakai et al., 2001).
Clearly more than one kinase is involved in phosphorylation
of IGFBP-1 because some phosphorylated IGFBP-1 transgene
product was present in the plasma from human IGFBP-1 trans-
genic mice (Dai et al., 1994). Furthermore, using a different
human IGFBP-1 transgene construct, Crossey and colleagues
(2000) were able to demonstrate hyperinsulinemia and glucose
intolerance in their transgenic mice.
On a molar basis, the IGFs are present in the circulation
in a 100-fold excess compared to insulin. Although the IGFs
have only about 5% of the insulin-like activity of insulin, they
represent the vast majority of the extractable insulin-like activ-
ity present in mammalian serum. Only a small percentage of
the circulating IGF-I is unbound. The actual percentage of the
total circulating IGF-I that is able to interact with the insulin
receptor and exert the hypoglycemic effect is unclear. The data
fromIGFBP-1transgenicmousemodelsareconsistentwiththe
hypothesis that the IGFs do indeed have some role in glucose
homeostasis. However, this may be a rather simplistic expla-
nation for the glucose intolerance observed in IGFBP-1 trans-
genic mice. Although glucose-intolerant IGFBP-1 transgenic
mice are characterized by hyperinsulinemia (Rajkumar et al.,
1996a; Crossey et al., 2000) and an increased pancreatic isletIGFS, IGFBPS, AND GLUCOSE HOMEOSTASIS 217
FIGURE 2
The hypoglycemic effects of IGF-I and des (1–3) IGF-I in wild-type and IGFBP-1 transgenic mice. (Modiﬁed from Rajkumar
et al., 1996b.)
size, number, and insulin content (Dheen et al., 1996), there
is also evidence of liver (Rajkumar and Murphy, 1999), adi-
pose tissue, and skeletal muscle insulin resistance (Rajkumar
et al., 1996b, 1999). The skeletal muscle insulin resistance was
demonstrablebothasimpairedglucoseuptakeinisolatedsoleus
muscleinresponsetoinsulinandalsoaselevatedplasmaamino
acids concentrations, a consequence of protein catabolism in
muscle (Figure 3). The skeletal muscle insulin resistance may
result from a disturbance in the relative ratio of IGF/insulin
hybrid receptors to insulin receptors. Reduced local IGF-I con-
centrations would reduce IGF-I receptor turnover, increase the
abundance of IGF-I receptor subunits, and favor formation of
hybrid receptors rather than insulin receptor heterodimers. Hy-
brid receptors are functionally more like IGF-I receptors than
insulinreceptorsandtheirabilitytotransducethemetabolicef-
fects of insulin are reduced (Siddle et al., 1994). However, the
lack of suitable reagents to measure hybrid receptor abundance
in rodents precludes directly testing this hypothesis.
In IGFBP-1 transgenic mice, pancreatic insulin content was
initially increased but declined with age and this decline was
accompaniedbythegradualonsetofhyperglycemia(Rajkumar
etal.,1996b),aphenomenonreminiscentofpancreaticexhaus-
tion observed in type II diabetes. Whether this represents an
inherentpancreaticdefectinIGFBP-1transgenicmice,glucose
toxicity, or a combination of both is unclear.
IGFBP-1 transgenic mice are characterized by intrauterine
growth retardation (Kabada et al., 1994; Crossey et al., 2002)
and abnormal placental morphology (Crossey et al., 2002). In
both rodent models and human studies, intrauterine growth
retardation has been associated with glucose intolerance, in-
sulin resistance, and the development of type II diabetes later
in life (Simmons et al., 2001; Yajnik, 2000). Furthermore, the
IGFs,particularlyIGF-II,areimportantinearlypancreaticislet
development (Petrik et al., 1999; Kido et al., 2002). Thus it is
possible that the intrauterine growth retardation that accom-
panies IGFBP-1 overexpression may have long-lasting effects
on glucose homeostasis, both in terms of tissue insulin re-
sistance and pancreatic insulin secretory capacity. In favor of
this hypothesis is the observation that glucose intolerance was
demonstrable in IGFBP-1 transgenic mice where the transgene218 L. J. MURPHY
FIGURE 3
The effect of insulin on glucose uptake into isolated soleus
muscle from wild-type and IGFBP-1 transgenic mice.
(Reproduced with permission from Rajkumar et al., 1996b.)
was expressed in utero (Rajkumar et al., 1995; Crossey et al.,
2002) but not in IGFBP-1 transgenic mice where postnatal in-
duction of the transgene expression was required (Dai et al.,
1994).
The IGFBP-1 transgenic mice demonstrated only modest
fasting hyperglycemia. However, glycemic excursions after in-
traperitoneal glucose were markedly increased compared to
wild-type mice (Figure 1) (Rajkumar et al., 1995). Glucose ad-
ministration to fasting mice with the consequent insulin release
would normally result in suppression of IGFBP-1 expression
(Murphy et al., 1991b). This reduction in IGFBP-1 levels fol-
lowing a glucose load in wild-type mice would enhance the hy-
poglycemic effect of IGF-I, possibly by increasing the free, un-
bound IGF-I concentration. In IGFBP-1 transgenic mice where
the expression of IGFBP-1 is constitutively up-regulated, this
compensatory mechanism would not occur.
Null-mutant IGFBP-1 mice have been generated and appear
normalaccordingtopreliminaryreports(Pintar,2001).Detailed
examination of glucose homeostasis in these mice has not as
yet been reported.
In summary, reports from various investigators provide
clear evidence for a role for IGFBP-1 in glucose homeosta-
sis. IGFBP-1 transgenic mice have many of the characteristic
features of type II diabetes mellitus. These include a period of
hyperinsulinemic normoglycemia and insulin resistance pre-
ceding fasting hyperglycemia (Rajkumar et al., 1996b).
IGFBP-2 and Glucose Homeostasis
Unlike IGFBP-I levels, plasma IGFBP-2 concentrations do
not show the same type of regulation as observed in response
to fasting and refeeding. IGFBP-2 levels are not increased after
an overnight fast and are not suppressed by glucose infusion in
fasting human subjects (Clemmons et al., 1991). After a pro-
longed fast in human subjects, only a slight increase in IGFBP-
2 levels was observed (Busby et al., 1988; Clemmons et al.,
1991). In rodents, both fasting and streptozotocin-induced di-
abetes markedly increase hepatic IGFBP-2 mRNA levels but
have little effect on serum IGFBP-2 levels (Rechler, 1993),
probably because of the long half-life of IGFBP-2 in the circu-
lation (Rechler, 1993).
Transgenic mice that overexpress IGFBP-2 have been gen-
erated (Hoeﬂich et al., 1999). These mice do not appear to dis-
play any gross abnormality in glucose homeostasis (Schneider
et al., 2000). IGFBP-2 null-mutant mice have also been gen-
erated. These mice also do not appear to have any signiﬁcant
abnormality in glucose homeostasis (Wood et al., 1993).
IGFBP-3 and Glucose Homeostasis
IGFBP-3 is by far the most abundant binding protein in the
circulation (Jones and Clemmons, 1995). Most of the IGF-I
and -II present in the circulation is bound to IGFBP-3. Levels
of IGFBP-3 are relatively stable because of the long half-life of
thisbindingprotein.ThereisnoapparentvariationsinIGFBP-3
levels in response to food. Both glycosylation and the ability to
complex with other circulating proteins (Collett-Solberg et al.,
1998), such as the acid-labile subunit (ALS) and ﬁbronectin
(Gui and Murphy, 2001), probably contribute to the long half-
live of IGFBP-3. The majority of IGFBP-3 in the circulation is
present as a ternary complex consisting of ALS, IGFBP-3, and
IGF-I or -II.
InadditiontoitsabilitytomodulateIGFavailability,IGFBP-
3 has been shown to have IGF-independent effects (Oh et al.,
1993, 1995; Valentinis et al., 1995). The IGF-independent ef-
fects that have so far been demonstrated include effects on cel-
lularproliferationandapoptosis.Theseeffectsmaybemediated
either via cell-surface binding proteins or nuclear binding sites
(Ohetal.,1993;Schedlichetal.,2000).BecauseIGFBP-3binds
to, and colocalizes with, retinoid × receptor (R×R)-α in the
nucleus (Liu et al., 2000), a transcription factor that is impor-
tant in glucose homeostasis, the potential exists for IGFBP-3
to have both IGF-dependent and IGF-independent effects on
glucose homeostasis. R×R-α is an important binding partner
for the peroxisome proliferator-activated receptor-γ (PPARγ),
anuclearproteinthatisinvolvedintranscriptionalregulationof
a variety of enzymes involved in glucose and lipid metabolism
(Juge-Aubry et al., 1997).IGFS, IGFBPS, AND GLUCOSE HOMEOSTASIS 219
FIGURE 4
Plasma glucose response to an intraperitoneal glucose challenge in wild-type and IGFBP-3 transgenic mice. The plasma glucose
excusions and the area under the glucose curve is shown. (Reproduced from Silha et al., 2002.)
Transgenic mice that overexpress IGFBP-3 at high levels
demonstrate disturbed glucose homeostasis (Silha et al., 2002).
In two different transgenic strains generated with different
transgene constructs, impaired glucose tolerance and reduced
insulin sensitivity were demonstrated (Figure 4). In both of
these transgenic strains, there was a signiﬁcant increase in the
circulating concentrations of IGFBP-3, IGF-I, and their ternary
complex (Modric et al., 2001). Total circulating IGF-I, the ma-
jority of which was present as ternary complex, was increased
∼1.5-fold compared to wild-type mice.
In both strains of IGFBP-3 transgenic mice, the hypo-
glycemic response to insulin was attenuated, although this was
moremarkedinthetransgenicmousestrainwhereskeletalmus-
cle expression of the IGFBP-3 transgene was greatest. In con-
trast, the hypoglycemic response to IGF-I was equally reduced
inbothtransgenicmousestrains.BothstrainsofIGFBP-3trans-
genic mice had similar levels of IGFBP-3 in the circulation;
however, the CMVBP-3 transgenic mice expressed the trans-
gene at higher levels in skeletal muscle, underlying the im-
portance of skeletal muscle in overall insulin sensitivity (Silha
et al., 2002). As discussed above, it has been suggested that
IGF-I sensitizes tissues, particularly muscle, to the effects of
insulin (Tomas et al., 1993). Local expression of the IGFBP-3
transgene in muscle may negate this effect.
Because circulating free IGF-I levels, and the ratio of free
to total IGF-I, were similar in both IGFBP-3 transgenic mouse
strains, these parameters, in contrast to skeletal muscle trans-
gene expression, do not appear to correlate with the insulin
resistance. It is likely that the measurement of these parameters
in the circulation does not reﬂect free IGF-I levels in skeletal
muscle or other tissue beds important in insulin-sensitive glu-
cose uptake where abnormal production of IGFBP-3 has been
generated by transgene expression.
The nuclear receptor R×R-α has been identiﬁed as a bind-
ing partner for IGFBP-3 in a yeast two-hybrid screen (Liu
et al., 2000). This observation, together with the previous re-
ports of nuclear localization of IGFBP-3 (Jacques et al., 1997;
Schedlich et al., 2000), indicates that IGFBP-3 may have a role
in modulating nuclear transcription of various genes involved
ingrowthandmetabolism.PPAR-γ isalsoabindingpartnerfor
R×R-α (Juge-Aubry et al., 1997). PPAR-γ is involved in the
regulationofgenesthatcontroldifferentiationofpreadipocytes
(Morrison and Farmer, 2000) and insulin sensitivity (Lehmann
et al., 1995; Steppan et al., 2001). Expression of R×R-α and
PPAR-γ mRNAs were similar in adipose tissue from IGFBP-
3 transgenic and wild-type mice (Silha et al., 2002). Resistin
mRNA, which encodes an adipokine whose expression is sup-
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similar in IGFBP-3 transgenic and wild-type mice (Silha et al.,
2002). Thus there was little evidence that the glucose intoler-
ance of the IGFBP-3 transgenic mice was in any way related to
theinteractionofIGFBP-3withtheR×R-α.Ifoverexpression
of IGFBP-3 in adipose tissue leads to increased interaction of
IGFBP-3 with R×R-α it does not appear to result in a distur-
bance in expression of R×R-α its binding partner PPAR-γ,o r
one of the known downstream effectors, resistin (Silha et al.,
2002). More likely the effect of overexpression of IGFBP-3 on
glucose homeostasis in transgenic mice involves mechanisms
similartothosethatresultinglucoseintoleranceintheIGFBP-1
transgenic mice.
The data generated from the IGFBP-3 transgenic mice
clearly demonstrate that IGFBP-3 has a role in glucose home-
ostasis, possibly by regulating free IGF-I levels in tissues. The
effects of IGFBP-3 overexpression cannot be explained by ei-
ther disturbances in growth hormone secretion, adiposity, or
circulating “free” IGF-I levels, because the two strains demon-
strateddifferencesinadiposity,growthhormonelevels,andfree
IGF-I levels yet both strains demonstrated disturbances in glu-
cose homeostasis (Silha et al., 2002). Local expression of the
transgeneinthetissues,particularlyinskeletalmuscle,appears
to be more important than perturbations in circulating levels of
IGF, free IGF, or growth hormone. High local levels of IGFBP-
3 may reduce the free IGF in the tissue and thereby decrease
the availability of IGF to the IGF-I, insulin receptor, or hybrid
IGF-I/insulin receptors. It is also possible that IGFBP-3 could
have direct, IGF-independent effects on glucose homeostasis,
but experiments to test this hypothesis have yet to undertaken.
IGFBP-3 null-mutant mice have been generated (Pintar,
2001). Preliminary reports suggest that these mice appear to be
phenotypically normal, although as yet there has been no de-
tailed investigation of glucose homeostasis (J. Pintar, personal
communications).
FUTURE DIRECTIONS AND
UNANSWERED QUESTIONS
Glucosehomeostasisrequiresacomplexinteractionofmany
factors, only some of which are currently understood. In addi-
tiontotheminute-to-minutemodulationofbloodsugar,glucose
homeostasis involves both short- and longer-term modulation
of insulin sensitivity and also partition of nutrients between
different organs and tissues. Short-term modulation of insulin
sensitivity would include diurnal variation in insulin sensitiv-
ity and variations that occur in relation to fasting and refeed-
ing. Longer-term modulation of insulin sensitivity relates to
changes in insulin resistance that accompany pubertal develop-
mentandsenescence.Circumstantialevidencesuggeststhatthe
IGF system is involved in both short- and long-term modula-
tion of insulin sensitivity. The binding proteins, by limiting the
availability of IGF to interact with the IGF-I receptor or hybrid
receptors, appear to have a role in regulating glucose home-
ostasis. The experimental observations reported to date clearly
establishthatIGF-Ihasaroleinglucosehomeostasis.However,
the exact molecular mechanisms involved remain unresolved.
The experiments with the IGFBPs, including those in which
transgenic and knockout mutant models have been utilized, are
relatively imprecise and have generated many more questions
than answers concerning the exact role of the IGFs in glucose
homeostasis. The IGFBP knockout mouse models have as yet
yielded little information, possibly because of the redundancy
in the binding proteins or because the appropriate experiments
have yet be done.
The overexpression of IGFBP-1 and IGFBP-3 in transgenic
mice has demonstrated the potential role of the IGFs in glu-
cose homeostasis but has also raised questions that can only
be addressed with more sophisticated experiments. For exam-
ple, what effects would the local overexpression of IGFBP-3
or IGFBP-1 in skeletal muscle, adipose tissue, or certain cells
in the brain or pancreas have on glucose homeostasis? Further-
more, the overexpression of both these binding proteins results
in some degree of intrauterine growth retardation, which may
have effects of resetting glucose homeostatic mechanisms. Ad-
ditional experiments with tissue-speciﬁc overexpression and
overexpression that can be reliably turned on and off at var-
ious stages in intrauterine and postnatal development may
well provide further insight into this area. The regulation of
post-translational modiﬁcation of the binding proteins has re-
ceivedlittleattention.Phosphorylationanddephosphyorylation
of IGFBP-1 have profound effects on the ability of IGFBP-1 to
modulate the hypoglycemic effects of IGF-I. These processes
arelikelytoberegulatedandmayhavearoleinmodulatingglu-
cose homeostasis. Similarly, further experiments are required
to understand the regulation and role of phosphorylation and
glycosylation of IGFBP-3.
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